News

The Phase 3 global, randomized, double-blind trial is evaluating CYRAMZA in combination with erlotinib, compared to placebo in combination with erlotinib, as a first-line treatment in patients with

According to Seres Therapeutics, the partners will research to assess microbiome-based approaches as a predictor for which cancer immunotherapies get the best response from patients. In addition, the

The study, also known as the HELP Trial (Hemodynamic Evaluation of Levosimendan in Patients with PH-HFpEF), is designed to enroll a total of 36 PH-HFpEF patients at up

Trazimera has been approved to treat human epidermal growth factor receptor-2 (HER2) overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Pfizer Oncology global president

This round of investment was co-led by Advantech Capital and CMBI, followed by Pudong Innotek. Also participating were existing investors Lilly Asia Venture (LAV) and OrbiMed Asia. “The

The priority review for Dupixent is for the treatment of adult patients whose CRSwNP is inadequately controlled. CRSwNP is a chronic disease of the upper airway. It is

Providing unparalleled levels of transparency and visibility, it empowers pharma actors to efficiently detect, act upon and ultimately prevent costly temperature excursions – currently causing billions worth of

The EC has approved Tecentriq in combination with Avastin, paclitaxel and carboplatin, for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC). Tecentriq, in

On March 2nd, 2019, TaiwanJ announced that its JKB-122, an effective phase 2 nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) drug candidate, had been successfully licensed out to